Outpatient medications associated with protection from COVID-19 hospitalization
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0282961 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Harpal Singh Sandhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY, United States of America. Hauptthemen laut MEDLINE: COVID-19, Metformin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NLM NIH HHS, U.S. National Library of Medicine.
Abstract (Originalsprache)
The COVID-19 pandemic remains the pre-eminent global health problem, and yet after more than three years there is still no prophylactic agent against the disease aside from vaccines. The objective of this study was to evaluate whether pre-existing, outpatient medications approved by the US Food and Drug Administration (FDA) reduce the risk of hospitalization due to COVID-19. This was a retrospective cohort study of patients from across the United States infected with COVID-19 in the year 2020. The main outcome was adjusted odds of hospitalization for COVID-19 amongst those positive for the infection. Outcomes were adjusted for known risk factors for severe disease. 3,974,272 patients aged 18 or older with a diagnosis of COVID-19 in 2020 met our inclusion criteria and were included in the analysis. Mean age was 50.7 (SD 18). Of this group, 290,348 patients (7.3%) were hospitalized due to COVID-19, similar to the CDC’s reported estimate (7.5%). Four drugs showed protective effects against COVID-19 hospitalization: rosuvastatin (aOR 0.91, p = 0.00000024), empagliflozin-metformin (aOR 0.69, p = 0.003), metformin (aOR 0.97, p = 0.017), and enoxaparin (aOR 0.88, p = 0.0048). Several pre-existing medications for outpatient use may reduce severity of disease and protect against COVID-19 hospitalization. Well-designed clinical trials are needed to assess the efficacy of these agents in a therapeutic or prophylactic setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of Louisville Speed School of Engineering, Louisville, KY, United States of America.
- University of Cincinnati College of Nursing, Cincinnati, OH, United States of America.
- Dr. Bing Zhang Department of Statistics, University of Kentucky, Lexington, KY, United States of America.
- Norton Infectious Diseases Institute, Norton Hospital, Louisville, KY, United States of America.
- Department of Surgery, Harvard Medical School, Boston, MA, United States of America.
ORCID-Profile: Harpal Singh Sandhu
Förderung
- NLM NIH HHS
- U.S. National Library of Medicine
Zitieren
APA
Sandhu, H. S., Lambert, J., Steckler, Z., Park, L., Stromberg, A., Ramirez, J., & Yang, C. J. (2023). Outpatient medications associated with protection from COVID-19 hospitalization. PLOS ONE. https://doi.org/10.1371/journal.pone.0282961
Vancouver
Sandhu HS, Lambert J, Steckler Z, Park L, Stromberg A, Ramirez J, et al. Outpatient medications associated with protection from COVID-19 hospitalization. PLOS ONE. 2023. doi:10.1371/journal.pone.0282961
BibTeX
@article{Sandhu2023,
author = {Sandhu, Harpal Singh and Lambert, Joshua and Steckler, Zach and Park, Lee and Stromberg, Arnold and Ramirez, Julio and Yang, Chi-Fu Jeffrey},
title = {Outpatient medications associated with protection from COVID-19 hospitalization},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0282961}
}
EUVIMED